TUDCA
Liver SupportPreclinicalAlso known as: Tauroursodeoxycholic Acid, Tauroursodiol, TURSO, Taurolite, UR-906, Xiong Dan (Traditional Chinese medicine black bear bile), Tauro-UDCA
TUDCA (tauroursodeoxycholic acid) is a hydrophilic bile acid formed by taurine conjugation of ursodeoxycholic acid (UDCA, the active ingredient in the widely-prescribed cholestasis medication Ursodiol). TUDCA occurs naturally in the bile of bears (particularly Asiatic black bears, where it comprises a substantial fraction of total bile acids), which is the source of its centuries-long use in traditional Chinese medicine as the preparation xiong dan (bear bile), where it has been used for liver disease, eye disease, and inflammatory conditions since at least the 7th century Tang dynasty.
Overview
At A Glance
TUDCA's mechanism of action operates through several distinct but overlapping pathways, making it unusual among bile acid therapeutics in having multiple pharmacologically meaningful modes of activity beyond simple bile-acid replacement.…
Mechanism of Action
TUDCA's mechanism of action operates through several distinct but overlapping pathways, making it unusual among bile acid therapeutics in having multiple pharmacologically meaningful modes of activity beyond simple bile-acid replacement.
Pathway 1: Bile acid pool modification. TUDCA's most straightforward mechanism is its direct effect on the bile acid pool. Administered orally, TUDCA is absorbed, joins the enterohepatic circulation, and — at sufficient doses — becomes a meaningful fraction of the circulating and biliary bile acid pool. The bile acid pool normally contains a mixture of more-hydrophobic (cytotoxic at high concentrations) and more-hydrophilic (non-toxic) species. Hydrophobic bile acids (lithocholic acid, deoxycholic acid, chenodeoxycholic acid) can damage cell membranes through detergent-like activity and can activate apoptosis pathways in hepatocytes under conditions of accumulation (cholestasis, defective transport). TUDCA — a highly hydrophilic conjugated bile acid — displaces more hydrophobic species, reduces total bile acid cytotoxicity, and stabilizes hepatocyte membranes. This is the mechanistic basis for UDCA and TUDCA use in cholestatic liver disease (PBC, PSC, intrahepatic cholestasis of pregnancy, progressive familial intrahepatic cholestasis).
Pathway 2: Endoplasmic reticulum (ER) stress reduction via chemical chaperone activity. The more novel and therapeutically expansive TUDCA mechanism is its action as a chemical chaperone — a small molecule that stabilizes protein folding intermediates and reduces aggregation of misfolded proteins. ER stress is induced when the demand for protein folding exceeds the ER's folding capacity, leading to accumulation of misfolded proteins. The cellular response (unfolded protein response, UPR) initially attempts to restore homeostasis through increased chaperone expression, reduced translation, and enhanced ER-associated degradation of misfolded proteins. If ER stress is severe or prolonged, the UPR shifts from adaptive to pro-apoptotic, triggering cell death through CHOP, JNK, and other mediators. TUDCA acts as an exogenous chemical chaperone that reduces misfolded protein accumulation, reduces UPR activation, and protects cells from ER-stress-induced apoptosis. This mechanism has been validated in numerous in vitro and in vivo models of: diabetes (protecting beta cells from ER-stress-induced dysfunction; Özcan et al. 2006 is the seminal paper); neurodegeneration (protecting neurons in Alzheimer's, Parkinson's, Huntington's, and ALS models); cardiovascular disease (reducing ER stress in atherosclerotic lesions and ischemic myocardium); ophthalmologic diseases (retinitis pigmentosa, diabetic retinopathy); and ischemia-reperfusion injury broadly.
Pathway 3: Mitochondrial protection. TUDCA has direct effects on mitochondrial function beyond its ER-stress effects. Specifically, TUDCA inhibits mitochondrial permeability transition pore (mPTP) opening, which is a key event in apoptotic cell death. By preventing mPTP opening, TUDCA stabilizes mitochondrial membrane potential, reduces cytochrome c release from mitochondria to cytosol, and prevents activation of caspase-dependent apoptosis. This mitochondrial stabilization mechanism is particularly relevant in neurodegeneration and ischemia-reperfusion contexts where mitochondrial dysfunction is a central pathogenic feature.
Pathway 4: FXR (farnesoid X receptor) modulation. Bile acids are natural ligands for FXR, a nuclear receptor that regulates bile acid homeostasis, lipid metabolism, glucose metabolism, and inflammation. TUDCA has relatively weak direct FXR agonism compared to more lipophilic bile acids, but contributes to modulation of FXR-dependent transcriptional programs that regulate bile acid synthesis (reducing the synthesis of more-toxic primary bile acids), lipid homeostasis (affecting triglyceride and HDL metabolism), and glucose metabolism (affecting hepatic gluconeogenesis and insulin sensitivity). This mechanism contributes to TUDCA's effects on metabolic syndrome and the observed improvements in lipid and glucose parameters in some clinical contexts.
Pathway 5: Anti-inflammatory and immunomodulatory effects. TUDCA reduces expression of inflammatory cytokines (TNF-α, IL-1β, IL-6) in multiple tissue contexts and downregulates NF-κB signaling. In hepatocytes, intestinal epithelium, macrophages, and neurons, TUDCA exerts anti-inflammatory effects that contribute to its therapeutic profile across diverse disease contexts. The exact molecular pathways linking TUDCA to NF-κB are incompletely defined but appear to involve both the chaperone effect (reducing ER-stress-induced inflammation) and direct cell-signaling modulation.
Pathway 6: Apoptosis pathway modulation beyond ER and mitochondria. Beyond the ER-stress and mitochondrial mechanisms described above, TUDCA modulates additional apoptotic pathways including Bax translocation to mitochondria, caspase activation, and downstream apoptotic signaling. The integrated effect is broad cytoprotection across multiple cell death pathways, which explains TUDCA's protective effects across diverse insult types (ischemia, toxin exposure, mechanical stress, misfolded protein accumulation).
Tissue distribution and pharmacokinetics. After oral administration, TUDCA is absorbed throughout the small intestine via passive and active transport. First-pass hepatic extraction is substantial — the liver efficiently takes up TUDCA from portal blood, which means hepatic tissue concentrations are much higher than systemic plasma concentrations. TUDCA is then re-secreted into bile, reabsorbed from the intestine, and re-enters the hepatic circulation in the standard enterohepatic cycle. This cycling means that the pharmacologic exposure in the liver is disproportionately large compared to systemic exposure, making TUDCA particularly well-suited to hepatic and biliary conditions. Systemic exposure is sufficient for some ER-stress effects in other tissues (evidence for brain penetration is mixed — TUDCA crosses the blood-brain barrier modestly but effectively enough to produce CNS effects in some models), but the pharmacokinetic profile is primarily liver-biased.
Comparison with UDCA. UDCA (the unconjugated parent compound) shares many of TUDCA's mechanisms but with somewhat different pharmacokinetics (less hydrophilic, less well absorbed orally, different conjugation profile). UDCA is FDA-approved for PBC and PSC; TUDCA is not approved for these indications in the US but is approved in some European markets. In head-to-head comparisons, TUDCA often shows equal or modestly superior efficacy for cholestatic liver biochemistry endpoints, likely due to its more favorable pharmacokinetics and direct activity without requiring hepatic conjugation. Clinically, UDCA is more widely prescribed in the US due to regulatory approval, while TUDCA is more widely used as a supplement and in European clinical practice.
Comparison with other chemical chaperones. Other chemical chaperones have been investigated (4-phenylbutyric acid / sodium phenylbutyrate, trimethylamine N-oxide, glycerol, betaine), with sodium phenylbutyrate being the most clinically developed — it is combined with TUDCA in the AMX0035 (Relyvrio) formulation. Sodium phenylbutyrate and TUDCA have complementary mechanisms — sodium phenylbutyrate acts as an HDAC inhibitor and ammonia scavenger in addition to chemical chaperone activity, while TUDCA provides the bile-acid and mitochondrial effects — which is the rationale for the AMX0035 combination product.
Overview
TUDCA (tauroursodeoxycholic acid) is a hydrophilic bile acid formed by taurine conjugation of ursodeoxycholic acid (UDCA, the active ingredient in the widely-prescribed cholestasis medication Ursodiol). TUDCA occurs naturally in the bile of bears (particularly Asiatic black bears, where it comprises a substantial fraction of total bile acids), which is the source of its centuries-long use in traditional Chinese medicine as the preparation xiong dan (bear bile), where it has been used for liver disease, eye disease, and inflammatory conditions since at least the 7th century Tang dynasty. Modern pharmaceutical manufacturing produces TUDCA synthetically without animal sourcing, eliminating the ethical and conservation concerns associated with bear bile harvesting while providing a consistent and pure active substance. TUDCA has prescription pharmaceutical status in several European countries (Italy, China) for cholestatic liver disease and is widely available as a dietary supplement in the United States and most Western markets for liver support and broader off-label use. Its rising popularity in three distinct user communities — anabolic steroid users seeking hepatic protection during oral cycles, longevity-focused biohackers interested in ER-stress and mitochondrial effects, and patients with neurodegenerative disease attracted by the landmark AMX0035 ALS trial data — has made TUDCA one of the most-discussed bile-acid therapeutics in research-chemical and supplement markets.
Structurally, TUDCA is the taurine-conjugated form of UDCA, which is itself the 7β-hydroxy epimer of chenodeoxycholic acid (CDCA). The taurine conjugation converts the hydrophobic primary bile acid into a more hydrophilic and bioavailable molecule, with the practical effect of improved intestinal absorption, reduced bile acid detergent activity (important for the safety profile — hydrophobic bile acids can damage cell membranes), and superior systemic distribution compared to unconjugated UDCA. TUDCA is a primary mammalian bile acid in some species (notably bears) and a minor bile acid in humans, representing <1% of total human bile acid pool under normal circumstances. Following oral administration in humans, TUDCA is absorbed in the small intestine, enters the enterohepatic circulation, and undergoes extensive first-pass hepatic extraction — meaning that most of an orally-administered dose is rapidly concentrated in the liver and biliary tree, providing high hepatic tissue exposure at relatively modest systemic plasma levels.
Functionally, TUDCA acts through multiple overlapping mechanisms that distinguish it from simpler hepatoprotective agents. The classical bile-acid function is replacement of more-toxic hydrophobic bile acids with the non-toxic hydrophilic TUDCA, reducing bile-acid-mediated hepatocyte damage in cholestatic conditions — this is the basis for UDCA's and TUDCA's longstanding use for primary biliary cholangitis (previously primary biliary cirrhosis), primary sclerosing cholangitis, and various cholestatic syndromes of pregnancy and genetic origin. Beyond this classical function, TUDCA is now recognized as a chemical chaperone — a small molecule that stabilizes protein folding and reduces endoplasmic reticulum (ER) stress. When cells experience stress that causes misfolded proteins to accumulate in the ER (a common feature of diabetes, neurodegeneration, ischemic injury, and many chronic diseases), the unfolded protein response (UPR) is activated, which can trigger cell death if the stress is prolonged. TUDCA's chemical chaperone activity reduces ER stress, reduces UPR activation, and has been shown in numerous preclinical models to protect cells from ER-stress-induced apoptosis. This mechanism underlies TUDCA's effects in diabetes (protecting pancreatic beta cells from ER-stress-induced dysfunction), Alzheimer's and Parkinson's models (reducing misfolded-protein-induced neuronal death), ALS (protecting motor neurons), retinitis pigmentosa and other retinal degenerative conditions, and a range of other pathologies where ER stress is a pathogenic factor.
The clinical evidence base divides into three tiers. Tier 1 (approved/standard of care): cholestatic liver disease — UDCA (the unconjugated form) has standard-of-care status for primary biliary cholangitis (PBC), where it improves liver biochemistry and in some populations reduces progression to liver transplantation. TUDCA is used in similar contexts in European pharmaceutical markets and shows equivalent or superior efficacy to UDCA for some endpoints. Tier 2 (emerging clinical evidence): ALS — the CENTAUR trial (Paganoni et al. 2020) evaluated AMX0035, a fixed-dose combination of TUDCA and sodium phenylbutyrate, in ALS patients and demonstrated 25% slower functional decline and significantly improved survival compared to placebo. FDA approval of AMX0035 under the brand name Relyvrio in 2022 represented the first approval of a TUDCA-containing medication for a non-cholestatic indication. (Relyvrio was subsequently withdrawn from the US market in April 2024 after the Phase 3 PHOENIX trial failed to confirm the Phase 2 benefit, producing active controversy about TUDCA's role in ALS.) Additional neurodegenerative disease trials for Parkinson's disease (including the UP-Parkinson's Phase 2 trial) are in progress. Tier 3 (mechanism-driven off-label use): bodybuilding/liver support during oral anabolic cycles, general antioxidant and "liver detox" supplementation, neuroprotection in the absence of disease, metabolic syndrome and insulin resistance support, and broad longevity applications. Tier 3 uses are driven by plausible mechanism and subjective reports rather than by direct clinical trial evidence in those specific contexts.
The bodybuilding and anabolic steroid context deserves specific mention because it drives much of the retail supplement-market demand for TUDCA. 17α-alkylated oral anabolic steroids (methylated compounds including oxandrolone, stanozolol, methandrostenolone, oxymetholone, anadrol, and others) are hepatotoxic, producing cholestatic hepatitis and liver enzyme elevations with chronic use. The bodybuilding community has long used UDCA and more recently TUDCA as hepatoprotective agents during oral steroid cycles, with the pharmacological rationale that bile-acid replacement and chemical-chaperone activity protect against cholestatic hepatotoxicity. Anecdotal reports and limited data support this use. Note that TUDCA does NOT reverse or prevent the underlying hepatotoxicity of 17α-alkylated steroids, nor does it allow safe long-term use of hepatotoxic substances — the pharmacologically honest framing is that TUDCA is a harm-reduction adjunct for users who are going to use oral anabolic steroids regardless, not an indication that oral anabolic steroids are safe when TUDCA is co-administered.
This entry covers TUDCA's bile-acid biology and chemical chaperone pharmacology, the traditional Chinese medicine history and transition to modern synthesis, the cholestatic liver disease evidence base, the CENTAUR ALS trial and subsequent FDA approval and withdrawal, the emerging Parkinson's disease work, the diabetes and metabolic research, the bodybuilding/steroid-user context with honest framing, practical dosing across indications, the relatively clean safety profile, drug interactions (limited but including cholestyramine and some others), appropriate stacking with milk thistle, NAC, and other hepatoprotective and antioxidant agents, and honest epistemic framing that separates the solid cholestatic-disease evidence from the ALS evidence (itself now uncertain post-PHOENIX) from the broader off-label longevity and general-health claims that remain largely mechanism-driven.
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
Not yet available
Molecular Mass
Not yet available
Chemical data is being compiled for this compound.
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
Absolute contraindications:
- Known hypersensitivity to TUDCA, UDCA, or other bile acid components — avoid further use
- Severe extrahepatic cholestasis due to mechanical bile duct obstruction — requires mechanical intervention, not bile acid therapy
- Severe active cholecystitis or biliary pancreatitis — defer bile acid therapy until acute condition resolved
- Completely obstructed gallbladder or bile duct — bile acid therapy may be inappropriate; address obstruction first
Relative contraindications and use with caution:
- Severe decompensated liver disease (Child-Pugh C) — use only under hepatology supervision
- Known or suspected severe pancreatic duct obstruction — discuss with specialist
- Pregnancy — use only when specifically indicated (intrahepatic cholestasis of pregnancy, ICP) under obstetrics guidance; not recommended for general supplementation during pregnancy
- Breastfeeding — limited data; discuss with obstetrics if use is needed
- Severe renal failure on bile acid sequestrants — timing of administration is critical; separate TUDCA from sequestrants by 4+ hours
- Concurrent cholestyramine, colestipol, or colesevelam — separate TUDCA dose by 4+ hours
- Concurrent aluminum-containing antacids — separate TUDCA dose by 2+ hours
- Active severe diarrhea — may be worsened by TUDCA; address diarrhea before beginning TUDCA
- Active inflammatory bowel disease flare — may worsen diarrhea; discuss with gastroenterology
- Known gallstones with recent symptoms — bile acid therapy may affect gallstone behavior; discuss with gastroenterology
- Severe hepatic cirrhosis with encephalopathy — use under hepatology guidance only
Special considerations:
- Source quality: supplement-channel TUDCA quality varies; prefer reputable manufacturers with third-party testing
- Confusion with UDCA: some products labeled TUDCA are actually UDCA; verify product identity
- Dosing precision: bulk powder dosing should be done by weight, not volume estimation
- Storage: keep dry, cool, and out of children's reach
Drug interactions requiring specific attention:
- Bile acid sequestrants (cholestyramine, colestipol, colesevelam): reduce TUDCA absorption; separate by 4+ hours. This is the most clinically significant TUDCA drug interaction.
- Aluminum-containing antacids: may reduce TUDCA absorption; separate by 2+ hours.
- Estrogen-containing oral contraceptives: theoretical increase in gallstone risk; usually manageable; discuss with prescribing physician if new TUDCA use on oral contraceptives.
- Fluoroquinolones: minimal interaction but separation of timing is prudent.
- Warfarin: TUDCA may theoretically affect warfarin absorption; monitor INR closely if initiating TUDCA on stable warfarin.
- Other medications: TUDCA has minimal CYP450 interactions; most medications can be safely continued alongside TUDCA.
Laboratory interference:
- Does not interfere with standard lipid, glucose, liver function assays
- Does not interfere with bile acid assays significantly except to elevate those specifically measuring TUDCA/UDCA
- No interference with standard drug screens
When to seek medical attention:
- Persistent worsening diarrhea: evaluate for other causes; temporarily stop TUDCA and discuss with clinician
- New abdominal pain, particularly right upper quadrant: evaluate for gallbladder or pancreatic pathology
- Jaundice (yellowing of skin or eyes): may indicate worsening of underlying liver disease; immediate evaluation
- Severe allergic reaction: facial swelling, rash, difficulty breathing — emergency evaluation
- Signs of severe liver dysfunction: severe fatigue, right upper quadrant pain, dark urine, jaundice
When to discontinue:
- Allergic or hypersensitivity reaction
- Persistent intolerable GI side effects despite dose reduction
- Worsening of underlying liver disease
- Before planned surgery or major procedures (discuss with surgical team)
- Pregnancy (unless specifically indicated for cholestasis of pregnancy under obstetrics guidance)
- No objective benefit after 6-month adequate trial for a specific indication
Post-discontinuation:
- TUDCA's bile acid effects are relatively rapid; washout is typically 1-2 weeks
- Liver function tests typically return to baseline or pre-TUDCA trajectory within 4 weeks
- No withdrawal effects
- Can be restarted after discontinuation if contraindication resolves
Honest framing: TUDCA at supplement doses has exceptionally few absolute contraindications and a clean interaction profile. The main safety considerations are ensuring source quality, separating from bile acid sequestrants, and monitoring for rare side effects. For specific clinical indications (PBC, ALS, metabolic disease), appropriate specialist supervision guides contraindication assessment.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
No listings found for TUDCA.
Research Score
0 PubMed studies
Quality Indicators
Data Completeness
50%Quick Facts
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is TUDCA and how is it different from regular UDCA?
TUDCA (tauroursodeoxycholic acid) is the taurine-conjugated form of UDCA (ursodeoxycholic acid). Both are hydrophilic bile acids with similar pharmacology, but TUDCA has several practical advantages: better oral absorption and bioavailability (the taurine conjugation makes it more hydrophilic and water-soluble), direct activity without requiring hepatic conjugation (UDCA must be conjugated to become fully active), more direct chemical chaperone effects on ER stress, and naturally occurring in mammalian bile (bears have particularly high TUDCA, which is the traditional bear bile used in Chinese medicine for over 1,000 years — modern TUDCA is synthesized without animal sourcing). UDCA (sold as Actigall, Urso) is FDA-approved in the US for primary biliary cholangitis (PBC). TUDCA is not FDA-approved for this indication in the US but is approved in several European markets (Italy) and widely used as a dietary supplement. In head-to-head trials for PBC, TUDCA shows equivalent or modestly superior efficacy to UDCA for key liver biochemistry endpoints (Crosignani et al. 1996, PMID 8781947). The practical choice in the US typically comes down to: UDCA for FDA-approved indications covered by insurance; TUDCA for supplement use, research applications, or for patients not adequately responding to UDCA alone.
Does TUDCA actually protect the liver during oral steroid use?
There is mechanistic rationale for TUDCA's hepatoprotective effects during oral anabolic steroid use, but the clinical evidence specifically for this context is limited. The mechanistic basis: 17α-alkylated oral anabolic steroids (methyltestosterone, oxandrolone, stanozolol, methandrostenolone, oxymetholone/anadrol, others) cause cholestatic hepatotoxicity — impaired bile flow with subsequent hepatocyte damage. TUDCA addresses cholestasis directly through its bile-acid-replacement and chemical-chaperone mechanisms; this is exactly the pharmacology used for other cholestatic conditions (primary biliary cholangitis, intrahepatic cholestasis of pregnancy). Observational and anecdotal data from the bodybuilding community suggest that TUDCA co-administration with oral steroids reduces AST/ALT elevations and mitigates liver function test abnormalities during cycles. What TUDCA does NOT do: (1) prevent the underlying hepatotoxicity mechanism — 17α-alkylated steroids are still liver-toxic, TUDCA mitigates rather than eliminates this; (2) make oral steroid use 'safe' at high doses or long durations; (3) prevent other steroid-related issues like lipid dysregulation, cardiac risk, or hormonal suppression; (4) allow continuous year-round oral steroid use without liver damage. The honest framing: TUDCA is a harm-reduction adjunct for users who are going to use oral anabolic steroids regardless, not an indication that oral anabolic steroids are safe when TUDCA is co-administered. Standard bodybuilding protocol: TUDCA 500-1,000 mg/day during cycle and 2-4 weeks post-cycle; monitoring liver function before, during, and after cycle.
What happened with Relyvrio (AMX0035) for ALS?
Relyvrio is a trade name for AMX0035, the fixed-dose combination of TUDCA 1,000 mg + sodium phenylbutyrate 3,000 mg twice daily, developed by Amylyx Pharmaceuticals specifically for ALS. The drug went through a complete rise-and-fall cycle in US regulatory history: (1) The Phase 2 CENTAUR trial (Paganoni 2020, PMID 32905678) demonstrated 25% slower functional decline on ALSFRS-R and approximately 6.5-month survival benefit in open-label extension analysis. (2) Based on CENTAUR data, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee narrowly recommended approval in September 2022 (7-2 vote), and FDA granted Accelerated Approval. (3) Amylyx committed to continuing development and conducting the Phase 3 PHOENIX trial to confirm efficacy. (4) The Phase 3 PHOENIX trial (2024) failed to meet its primary endpoint — AMX0035 did not show statistically significant efficacy versus placebo in the larger and longer confirmatory trial. (5) In April 2024, Amylyx voluntarily withdrew Relyvrio from the US and Canadian markets. This has created substantial controversy: some argue CENTAUR was a false positive that PHOENIX correctly identified; others argue the benefit is real but smaller than CENTAUR suggested, and ALS heterogeneity may have diluted the effect in PHOENIX; many ALS patients and advocates continue to use TUDCA + sodium phenylbutyrate based on CENTAUR data and anecdotal benefit, given limited alternative ALS treatments. The AMX0035 withdrawal does not affect the mechanistic rationale for TUDCA in ALS — it affects only whether AMX0035 specifically produces meaningful clinical benefit. Research continues on TUDCA in ALS independent of the commercial drug status.
What doses of TUDCA should I take?
Dosing varies substantially by indication and user context. General guidelines: (1) Beginner / general liver support / mild cholestatic concerns: 250-500 mg/day, typically as 250 mg twice daily with meals. (2) Standard supplement-use dose: 500 mg/day. (3) Cycle support during oral anabolic steroid use: 500-1,000 mg/day during cycle; 1,000 mg/day post-cycle for 4-6 weeks. (4) Primary biliary cholangitis (PBC) or cholestatic liver disease: 750 mg/day divided with meals under hepatology supervision. (5) Metabolic syndrome / NAFLD protocols: 500-1,000 mg/day. (6) ALS protocol (AMX0035/CENTAUR-style): 2,000 mg/day (1,000 mg BID) typically combined with sodium phenylbutyrate 6,000 mg/day under neurology supervision. (7) Research/advanced metabolic: 1,500-2,000 mg/day under clinical or research context. Dosing principles: always take with meals for optimal absorption; divide daily dose into 2-3 portions; maintain consistent daily timing; separate from bile acid sequestrants (cholestyramine, colestipol, colesevelam) by 4+ hours; separate from aluminum antacids by 2+ hours. Higher doses (>1,000 mg/day) are more likely to cause GI side effects (diarrhea) but are tolerated by most users when introduced gradually.
What are the side effects of TUDCA?
TUDCA has a favorable safety profile with minimal side effects at standard supplement doses. Common side effects (5-15% at 250-1,000 mg/day): mild diarrhea or loose stools (most common — often resolves with continued use or dose reduction), mild nausea (uncommon, typically resolves), mild gastrointestinal discomfort including bloating and altered bowel habits. Less common (1-5%): skin rash, temporary pruritus, changes in stool appearance, rare mild liver enzyme fluctuations. High-dose side effects (ALS-level doses 2,000+ mg/day): more prominent GI side effects (20-30% incidence of bothersome diarrhea at very high doses), occasional dizziness, transient headache. Rare serious events: severe allergic reactions (extremely rare), worsening of severe cholestasis (rare paradoxical response), significant hyperbilirubinemia (rare at supplement doses). Drug interactions are limited and manageable: absolutely avoid simultaneous administration with bile acid sequestrants (cholestyramine, colestipol, colesevelam — separate by 4+ hours); separate from aluminum antacids by 2+ hours; TUDCA has minimal CYP450 interactions, giving it a very clean interaction profile with most prescription medications. Pregnancy safety: TUDCA has been used for intrahepatic cholestasis of pregnancy; UDCA is FDA Pregnancy Category B. Long-term safety: decades of UDCA use for PBC establish acceptable long-term safety; TUDCA's shorter clinical history adds reasonable confidence. Overall, TUDCA is one of the safer supplements and clinical agents in common use for its indications.
Will TUDCA interact with my medications?
TUDCA has an exceptionally clean drug-drug interaction profile because it does not significantly affect the cytochrome P450 (CYP450) enzyme system that mediates most pharmaceutical interactions. The most clinically significant interaction is with bile acid sequestrants — cholestyramine, colestipol, and colesevelam — which bind TUDCA in the intestine and reduce absorption. If you use any of these, separate TUDCA dose by 4+ hours (typically take TUDCA with meals and sequestrant at other times). Second major interaction: aluminum-containing antacids (some preparations like Mylanta, Maalox, AlternaGEL) can reduce TUDCA absorption; separate by 2+ hours. Other medications that require attention: estrogen-containing oral contraceptives (theoretical increase in gallstone risk when combined with bile acid therapy, clinical significance unclear), warfarin (TUDCA may theoretically affect absorption; monitor INR when initiating), fluoroquinolones (minimal interaction but timing separation prudent). Medications that are generally SAFE to combine with TUDCA: statins, metformin, ACE inhibitors, beta-blockers, PPIs, SSRIs, mood stabilizers, antihypertensives, most antibiotics, NSAIDs. TUDCA is considered compatible with the vast majority of prescription medications without dose adjustment. If starting TUDCA while on multiple medications, a pharmacist or clinical review is reasonable but typically no changes are needed. For PBC or severe cholestatic disease management, hepatology or gastroenterology coordination is appropriate.
Can I take TUDCA with alcohol or during heavy drinking periods?
TUDCA is pharmacologically compatible with alcohol and does not have significant acute interactions with ethanol. The more important question is: what are you trying to accomplish? TUDCA has real hepatoprotective mechanisms that are mechanistically relevant to alcohol-induced hepatocyte injury: bile-acid-replacement effects, ER stress reduction, mitochondrial protection, and anti-inflammatory effects. There are not specific well-designed clinical trials of TUDCA for alcohol-related liver disease, but the mechanism is plausible. However, TUDCA does NOT: (1) prevent alcoholic liver disease in heavy drinkers, (2) allow safe continued heavy alcohol use, (3) reverse established alcohol-related liver damage. If you are concerned about liver function due to alcohol use: the most important intervention by far is reducing or eliminating alcohol. TUDCA at 500-1,000 mg/day may provide additional hepatoprotective support for individuals with moderate alcohol use and mild liver enzyme elevation, but it cannot substitute for addressing the underlying alcohol pattern. If you are considering using TUDCA to protect during periods of heavy alcohol use: that is not a scientifically-supported protocol and may provide false reassurance that leads to continued harmful drinking. If you are a current heavy drinker with concerns about liver function: consult a clinician about liver function testing (AST, ALT, GGT, alkaline phosphatase, bilirubin), and address the alcohol use with professional support if needed. TUDCA can be a reasonable adjunct but it should not be the centerpiece of alcohol-related liver protection.
How do I know if TUDCA is actually working for me?
Monitoring depends on indication. For general liver support or cholestatic conditions: track liver function tests (ALT, AST, GGT, alkaline phosphatase, bilirubin — particularly direct bilirubin for cholestasis) at baseline and 8-12 weeks. Reduction in ALT, AST, GGT, and alkaline phosphatase is the primary biochemical marker of TUDCA response. Subjective improvements to track: reduced fatigue, improved appetite, reduced pruritus (if cholestatic), improved digestive comfort. For bodybuilding cycle support: track liver function tests before, mid-cycle, end of cycle, and post-cycle recovery. Expected: attenuation of cycle-induced AST/ALT elevation compared to previous cycles without TUDCA. For metabolic syndrome / NAFLD: track liver enzymes, HbA1c, fasting insulin, triglycerides, HDL; combined with lifestyle interventions, improvements are typically gradual over months. For ALS: track ALSFRS-R (functional rating scale) every 1-3 months; track fine motor function, gait, breathing; track subjective well-being and activities of daily living. Expect modest slowing of progression rather than improvement. For Parkinson's disease: track UPDRS and subjective symptom quality; expect possible modest improvements. For retinal degenerative disease: ophthalmologic follow-up including visual field testing, OCT, visual acuity testing. For general longevity / healthspan: track broader markers of health (lipid profile, metabolic markers, inflammatory markers, possibly biological age markers) at 6-12 month intervals. Most users will not have dramatic subjective changes — TUDCA works primarily through preventive and mechanistic effects rather than producing symptomatic benefit. If no objective or subjective change after 6 months of adequate-dose use, reassess whether to continue. Combine TUDCA use with lifestyle factors (adequate protein, healthy weight, exercise, alcohol moderation, adequate sleep) that amplify any TUDCA benefit.
Is TUDCA ethical — doesn't it come from bears?
TUDCA has a mixed history and a clear contemporary answer. Historically, TUDCA was harvested from Asiatic black bear bile — a Chinese traditional medicine practice that continues today in some commercial bear bile farming operations that are widely condemned as cruel and environmentally unsustainable. Bear bile farming involves keeping live bears in small cages with surgical catheters draining bile, with significant animal suffering. Wild Asiatic black bears are classified as vulnerable and their populations have been reduced by bile trade demand. All of this is legitimately problematic and many ethical and environmental advocates oppose traditional bear bile products. Modern pharmaceutical and supplement-grade TUDCA is synthetically produced using microbial biotransformation or chemical synthesis from bovine-derived cholic acid. It does not come from bears and does not contribute to bear exploitation. Reputable TUDCA supplement and pharmaceutical manufacturers use synthetic TUDCA exclusively. When purchasing TUDCA, look for products labeled 'synthetic', 'non-bear-derived', or 'vegetarian' — most reputable US and European manufacturers provide this information. Products that do not clarify the source should be treated with skepticism. The traditional Chinese medicine framework that originally described bear bile benefits is being served by modern synthetic TUDCA without the ethical and conservation concerns of bear bile harvesting. So the ethical answer: yes, you can use TUDCA without contributing to bear exploitation, by choosing synthetic products from reputable manufacturers. The synthesis process does not involve bears at any step.
Does TUDCA help with neurodegenerative diseases beyond ALS?
The preclinical evidence for TUDCA in neurodegenerative disease is substantial across multiple disorders, but human clinical trial evidence is less mature. Established or emerging clinical evidence: (1) ALS — CENTAUR Phase 2 trial positive, PHOENIX Phase 3 trial negative; current status controversial but many still use TUDCA (or AMX0035-style TUDCA+phenylbutyrate combination) for ALS. (2) Parkinson's disease — UP-Parkinson's Phase 2 trial in progress; preclinical evidence strong. (3) Huntington's disease — preclinical evidence of TUDCA protection in R6/2 mouse model (Keene 2002 PMID 11796239) and related models; human trials limited. (4) Alzheimer's disease — preclinical evidence of amyloid-β protection; human trials preliminary. (5) Retinitis pigmentosa and other retinal degenerative diseases — preclinical evidence strong; some ophthalmology practices use TUDCA clinically; limited but positive human data. Mechanistic rationale for neurodegenerative benefit is coherent: neurodegenerative diseases involve misfolded protein accumulation and ER stress as common pathogenic factors, and TUDCA's chemical chaperone activity addresses these mechanisms. Practical framing: For diagnosed neurodegenerative disease, TUDCA is reasonable as an adjunctive therapy under specialist guidance — typically 500-2,000 mg/day depending on condition and specialist guidance. The evidence is substantial enough to warrant consideration but not so definitive that TUDCA should be presented as a proven treatment. Combination approaches (TUDCA + sodium phenylbutyrate for ALS-style protocols, TUDCA + mitochondrial cofactors like CoQ10 and creatine, TUDCA + specific disease-modifying therapies for respective conditions) are common in clinical practice. For general neuroprotection in the absence of diagnosed disease, TUDCA is speculative and should be considered as part of a broader healthspan framework rather than a specific intervention.
Research Tools
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
